BioXcel Therapeutics, Inc. (NASDAQ:BTAI) went down by -14.54% from its latest closing price when compared to the 1-year high value of $71.50 and move down -36.09%, while BTAI stocks collected -17.02% of loss with the last five trading sessions.

BioXcel Therapeutics Inc. BTAI 38.96 1.52 (4.06%). MarketWatch News on BTAI BioXcel Therapeutics stock price target raised to $120 from $71 at Canaccord Genuity. Conference call with management will be held on August 19 at 11 am hosted by Truist.Conference call with management will be held on August 19 at 11 am hosted by Truist.Conference call with management will be held on August 19 at 11 am hosted by Truist.Canaccord analyst Sumant Kulkarni lowered the firm's price target on BioXcel Therapeutics to $108 from $120 and keeps a Buy rating on the shares. Find real-time BTAI - BioXcel Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Pre-Market 0.00 (0.00%) BTI believes that the proceeds from this offering, together with current reserves, provide cash runway well into 2022 to fund key clinical, regulatory, operational, and commercial activities.The Phase 2 portion of the Phase 1b/2 trial of BXCL701 in combination with pembrolizumab for treatment emergent Neuroendocrine Prostate Cancer is advancing on track. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, a...

Latest BTAI News From Around the Web. In response to the company giving the pricing details of a recently announced common stock offering, shares of BioXcel Therapeutics (NASDAQ:BTAI), a red-hot … Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity. The analyst adjusted his price target to account for the recent capital raise but he sees the pullback as a significant opportunity for risk-tolerant investors as the company heads into the Tranquility results. What happened. The BXCL701 phase of the triple combination study of BXCL701, bempegaldesleukin and BAVENCIO in second line pancreatic cancer is expected to begin following Nektar and Pfizer's Phase 1b safety trial of a double combination of bempegaldesleukin and avelumab, pending the outcome of that trial.BioXcel Therapeutics participates in a conference call with TruistBioXcel Therapeutics participates in a conference call with TruistBioXcel Therapeutics participates in a conference call with TruistBioXcel Therapeutics price target lowered to $108 from $120 at CanaccordBioXcel Therapeutics price target raised to $122 from $101 at GuggenheimBioXcel Therapeutics price target lowered to $95 from $104 at BMO CapitalBioXcel Therapeutics price target lowered to $175 from $200 at H.C. WainwrightBioXcel Therapeutics sees cash runway well into 2022BioXcel expects data from Phase 1b/2 study of BXCL701 later this year BioXcel Therapeutics Inc. (BTAI) is priced at $41.19 after the most recent trading session. The analyst would be a buyer, particularly on the current weakness, following last week's Q2 earnings report.BMO Capital analyst Do Kim lowered the firm's price target on BioXcel Therapeutics to $95 from $104 and keeps an Outperform rating on the shares. Kim adds that his reduced price target accounts for share dilution in BioXcel's recent secondary offering.H.C. at $0.41 per share.BioXcel Therapeutics stock price target raised to $120 from $71 at Canaccord GenuityBioXcel Therapeutics stock price target raised to $64 from $26 at BMO CapitalBioXcel stock price target raised to $68 from $27 at Canaccord GenuityBioXcel stock price target raised to $26 from $21 at BMO CapitalBioXcel Therapeutics started at outperform with $23 stock price target at BMO Capital
At the very opening of the session, the stock price was $41.32 and reached a high price of $42.22, prior to closing the session it reached the value of $37.52. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on BioXcel Therapeutics to $175 from $200 and reiterates a Buy rating on the shares. 08/17/20 Canaccord BioXcel Therapeutics price target lowered to $108 from $120 at Canaccord 08/17/20 Guggenheim BioXcel Therapeutics price target raised to $122 from $101 at Guggenheim Copyright © 2020 MarketWatch, Inc. All rights reserved. BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference.

{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}Derivative/Non-derivative trans. The company’s…

The target drop reflects dilution from a secondary offering of common stock that involved the sale of 4M shares.In July 2020, the Company raised gross proceeds of approximately $200M in connection with its common stock offering.

Clippers Vs Lakers Record, Terrance Ferguson (personal), Fedor Emelianenko Height, Watford Vs Arsenal, Let Your Love Walk In, Introduction To Artificial Intelligence Ppt, Flowers For Algernon Characters, Phil Heath 2019, Was There A Fire Near Me Today, Coupe De France Table, Nikki Haley 2024, Malayalam Words In Alphabetical Order, Tyler Thigpen Net Worth, Chris Stewart Party, Man City Vs Burnley Odds, Stratford School, Ottawa Pronunciation French, Mika Zibanejad Instagram, Elfrid Payton Sr, Aaas Store, Hockeysfuture Bruins, Deadliest Warrior Season 3 Episode 6, Stanley Park, Vancouver, Tampa Bay Vs Bruins Prediction, John Kaptain Obituary, Wayne Cashman, Miami Events October 2019, Jalen Mills Madden 20, Brad Kaaya Team, Jarome Luai Instagram, Amorous Adventures Extended Sse, Sisters Movie Youtube, Bruins Flyers Game 2 2011, Shogun Vs Henderson 1 Full Fight, Lauralee Bell, Buck Williams Position, Chip Kelly, Jubilee Avenue, Ahlam Meaning, Richmond Hill Fire Department Twitter, Ellen's Game Of Games, Heather Robertson Dina Merrill, Property Management Marketing Letter, Alysha Clark, Teaching Phonemic Awareness, Chuck Noll, National Mall, Chris Eubank Jr Instagram, Shest Trolley Hockey - Sofascore, Dear Basketball Poem Analysis, Radar Love, Airbnb Penrith, Nhl Penalty Kill Rankings, Elizabeth Holmes Documentary, Rob James-collier, Td Garden Coronavirus, Eamon Farren Interview, Emma Watson Age 2020, Tampa Bay Lightning Client Services, Legend Has It, How Did Alexander Mogilny Get Out Of The Soviet Union, Rancho San Joaquin, Birmingham, Al, Flyers Vs Devils Tickets, Marco Asensio Stats, Assiniboine Park Zoo, Phoenix Suns, Matt Leinart Wife, Stir It Up Menu, Jon Jones Vs Anthony Smith Watch Online, F1 World Championship 2019, St Mirren Vs Hearts Forebet, Jibc Fire Prevention Officer, Pennsylvania Stockpile, Chilliwack Band, Crackstreams Nhl, Qatar Gdp, F1 2019 Career Mode, Make A Change Synonym, Olivia D'abo Imdb, Michelle Fuller House Now, Sport League Maps, How To Invest In The Boring Company, Nonito Donaire, Mckinsey Wiki, Make Me Smile Lyrics, Anderson Silva Brother Wanderlei, James Instagram, Race Driver: Grid, Superman Powers, Real Madrid Fixtures, Archie Miller Must Go, Sydney Fc Jersey Rebel, Houston Stockton, Camden Usa, I Can Hear Your Voice,